Five-year follow-up of nivolumab treatment in Japanese patients with esophageal squamous-cell carcinoma (ATTRACTION-1/ONO-4538-07)

ConclusionOur follow-up analysis of more than 5  years is currently the longest and is the first to demonstrate that nivolumab has long-term efficacy and safety for advanced ESCC.

Source: Esophagus - May 16, 2021 Category: Gastroenterology Source Type: research